Cited by 651Science, Research, and MedicineHistorical Medical Research and TreatmentsGeneral Medicine and Therapeutics

The DOI matches its Crossref record.

Trends in clinical success rates and therapeutic focus

Dowden, Helen, Munro, Jamie·2019·Nature Reviews Drug Discovery

DOI 10.1038/d41573-019-00074-z

Open this paper in CoChat — free account

Integrity signals

Registry

Crossref · 10.1038/d41573-019-00074-z

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Sorted by citations

Items 301–400 of 651

In silico Pharmacokinetic and Toxicity Prediction of Compounds from Andrographis paniculata (Burm.f.) Nees.
Izatunnafis, I., Murti, Y. B., & Sudarmanto, B. S. A. (2023) · Journal of Food and Pharmaceutical Sciences · doi:10.22146/jfps.7436 · Cited by 7
“Thus, pharmacokinetic screening is needed [14,15].”
Empirical Analysis of Drug Targets for Nervous System Disorders
Mueller, L. G., Slusher, B. S., & Tsukamoto, T. (2024) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.3c00676 · Cited by 7
Prioritization of therapeutic targets for cancers using integrative multi-omics analysis
Jin, X., Mei, Y., Yang, P., Huang, R., Zhang, H., Wu, Y., Wang, M., He, X., Jiang, Z., Zhu, W., et al. (2024) · Human Genomics · doi:10.1186/s40246-024-00571-2 · Cited by 9
Lipid membrane-based therapeutics and diagnostics
de Carvalho, P. M. B., Makowski, M., Domingues, M. M., Martins, I. C., & Santos, N. C. (2021) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2021.108858 · Cited by 7
New high-throughput screening detects compounds that suppress pancreatic stellate cell activation and attenuate pancreatic cancer growth
Sagara, A., Nakata, K., Yamashita, T., Guan, W., Zhong, P., Matsumoto, S., Endo, S., Iwamoto, C., Shindo, K., Ikenaga, N., et al. (2021) · Pancreatology · doi:10.1016/j.pan.2021.04.002 · Cited by 7
Increasing the reproducibility of research will reduce the problem of apophenia (and more)
Jones, P. M., & Martin, J. E. (2021) · Canadian Journal of Anesthesia/Journal canadien d anesthésie · doi:10.1007/s12630-021-02006-1 · Cited by 8
“Les médicaments qui se rendent aux tests humains officiels dans les essais de phase 1 et 2 ont également un taux d’échec très élevé de 85-93 %.(15) Les chances qu’un médicament soit véritablement efficace augmentent quelque peu dans les essais de phase 3, parce que le travail préliminaire déjà effectué a éliminé de no…”
BackgroundInfluential
Integrated Bioinformatics Analysis Identified ASNS and DDIT3 as the Therapeutic Target in Castrate-Resistant Prostate Cancer
Jung, A. R., Shin, S. Y., Kim, M. Y., Ha, U., Hong, S., Lee, J. Y., Kim, S. W., Chung, Y., & Park, Y. H. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25052836 · Cited by 7
“Despite the long timeframe and financial investments in this process, the success rate in clinical development has been low [13].”
Background
Conformation, virtual cocrystal screening, synthesis and determination of dipyridamole
Yi, D., Dong, Y., Qi, M., Hong, M., Zhu, B., & Ren, G. (2024) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2024.139259 · Cited by 6
The topology of molecular representations and its influence on machine learning performance
Rottach, F., Schieferdecker, S., & Eickhoff, C. (2025) · Journal of Cheminformatics · doi:10.1186/s13321-025-01045-w · Cited by 10
“In addition, most drug candidates fail in the later phases of clinical trials and drug approval [3, 4], which is mostly attributed to insufficient drug-like properties, unacceptable toxicity and lack of clinical efficacy [5].”
FedECA: federated external control arms for causal inference with time-to-event data in distributed settings
du Terrail, J. O., Klopfenstein, Q., Li, H., Mayer, I., Loiseau, N., Hallal, M., Debouver, M., Camalon, T., Fouqueray, T., Castro, J. A., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-62525-z · Cited by 6
“However, it was shown to be already detrimental to the statistical analysis (see Supplementary Figs.3 and 11 and Supplementary Table13).”
History and Evolution of Innovations in Clinical Pharmacology
Lesko, L. J., & van der Graaf, P. H. (2025) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.70048 · Cited by 7
A cytokine receptor–targeting chimera toolbox for expanding extracellular targeted protein degradation
Kumru, K. S., Yao, Z. W., Holmes, B. B., Zhao, F., Zhang, Y., Ferrara, E., Peters-Clarke, T. M., Leung, K. K., & Wells, J. A. (2026) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2524129123 · Cited by 8
The evolving global landscape of first-in-class oncology drug innovation
Mao, X., Wang, Z., Kong, S., Yang, Y., Dreyer, N. A., Ba, Y., Lotze, M. T., Zhan, Q., & Li, G. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-026-02606-7 · Cited by 6
Building Human In Vitro 3D Models to Replace Animal Studies During Drug Discovery Research: Scientific, Ethical and Regulatory Considerations
Vangala, S., Saxena, U., & Chandran, C. S. (2022) · Springer eBooks · doi:10.1007/978-981-19-1379-2_29 · Cited by 6
Analysing potent biomarkers along phytochemicals for breast cancer therapy: an in silico approach
Shekar, N., Vuong, P., & Kaur, P. (2023) · Breast Cancer Research and Treatment · doi:10.1007/s10549-023-07107-7 · Cited by 6
The interplay between product development failures and alliance portfolio properties in the formation of exploration versus exploitation alliances
Bae, J., & Özmel, Ü. (2024) · Journal of Business Research · doi:10.1016/j.jbusres.2024.114622 · Cited by 6
Evaluation of Anti‐inflammatory Activity of Garlic Extracts in 3D Bioprinted Skin Equivalents
Kang, M. S., Jang, H. J., Kim, J., Jo, H. J., Park, K. M., Chung, Y., & Han, D. (2024) · Advanced NanoBiomed Research · doi:10.1002/anbr.202400007 · Cited by 8
Accelerated approvals: Early-phase success or premature authorization?
Mao, X., Alexander, G. C., & Li, G. (2024) · Cancer Cell · doi:10.1016/j.ccell.2024.09.005 · Cited by 6
Transforming drug discovery: the impact of AI and molecular simulation on R&D efficiency
Iwata, H. (2024) · Bioanalysis · doi:10.1080/17576180.2024.2437283 · Cited by 9
Toxicity of Combinations of Kinase Pathway Inhibitors to Normal Human Cells in a Three-Dimensional Culture
Nejad, P. R., Thakuri, P. S., Singh, S. K., Lamichhane, A., Heiss, J., & Tavana, H. (2021) · SLAS TECHNOLOGY · doi:10.1177/24726303211008858 · Cited by 6
Nano-based formulations as an approach for providing a novel identity for organoselenium compounds
Sari, M. H. M., Ferreira, L. M., Prado, V. C., Nogueira, C. W., & Cruz, L. (2022) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2022.07.018 · Cited by 8
US FDA 505(b)(2) NDA clinical, CMC and regulatory strategy concepts to expedite drug development
Salminen, W. F., Aloba, O., Drew, A., et al. (2023) · Drug Discovery Today · doi:10.1016/j.drudis.2023.103618 · Cited by 6
The rise of spin-offs: Fueling pharmaceutical innovation through collaboration
Yashiro, K., Lim, Y., Sengoku, S., et al. (2023) · Journal of Open Innovation Technology Market and Complexity · doi:10.1016/j.joitmc.2023.100200 · Cited by 6
A translational framework of genoproteomic studies for cardiovascular drug discovery
Yang, Z., Zhao, J. V., Qi, Y., Deng, X., Ji, Z., & Liu, J. (2024) · npj Cardiovascular Health · doi:10.1038/s44325-024-00015-9 · Cited by 6
Probing biological mechanisms with chemical tools
Kang, C., & Keller, T. H. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.104656 · Cited by 6
Gellan Gum Promotes the Differentiation of Enterocytes from Human Induced Pluripotent Stem Cells
Qiu, S., Kabeya, T., Ogawa, I., et al. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12100951 · Cited by 6
“Discussion According to the FDA, the clinical success rate during novel drug development is less than 10% [35].”
Background
Recent trends in interorganizational deal networks in pharmaceutical and biotechnology industries
Yashiro, K., Lim, Y., Sengoku, S., et al. (2022) · Drug Discovery Today · doi:10.1016/j.drudis.2022.103483 · Cited by 6
Effectively utilizing publicly available databases for cancer target evaluation
Croft, D. R., Lodhia, P., Lourenco, S. D. S., & MacKay, C. (2023) · NAR Cancer · doi:10.1093/narcan/zcad035 · Cited by 7
Generating Customized Compound Libraries for Drug Discovery with Machine IntelligencePreprint
Moret, M., Friedrich, L., Grisoni, F., et al. (2019) · ChemRxiv · doi:10.26434/chemrxiv.10119299.v1 · Cited by 6
Predicting successes and failures of clinical trials with an ensemble LS-SVRPreprint
Hong, Z.-Y., Shim, J., Son, W., & Hwang, C. (2020) · medRxiv · doi:10.1101/2020.02.05.20020636 · Cited by 6
“The probability of launch from entry to phase I has also remained below 10% [2].”
Background
Exploring the Impact of Pharmacological Target-Mediated Low Plasma Exposure in Lead Compound Selection in Drug Discovery – A Modeling Approach
Xu, M., Sun, D., & An, G. (2024) · The AAPS Journal · doi:10.1208/s12248-024-00979-7 · Cited by 5
“%) and safety concerns (> 20%), with the rest being strategic realignment, and commercial or operational reasons (7–10).”
Translational PBPK/PD modeling in drug discovery: A CRO perspective
Esposito, S., & Cebrián, D. Á. (2025) · Drug Discovery Today · doi:10.1016/j.drudis.2025.104427 · Cited by 5
Integrated Network Pharmacology and Molecular Dynamics Reveal Multi-Target Anticancer Mechanisms of Myrtus communis Essential Oils
Bayoudh, A., Tarhouni, N., Mansour, R. B., Mekrazi, S., Sadraoui, R., Kriaa, K., Ahmed, Z., Soussi, A., Kallel, I., & Hadrich, B. (2025) · Pharmaceuticals · doi:10.3390/ph18101542 · Cited by 7
Improving ADME Prediction with Multitask Graph Neural Networks and Assessing Explainability in Lead Optimization
Ito, S., Koyama, T., Matsumoto, S., et al. (2025) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.5c00758 · Cited by 5
Digital health technology use in clinical trials of rare diseases: a systematic review
Mao, X., Zeng, D., Wang, X., Pearce, D. A., Baynam, G. S., Chavannes, N. H., Chung, W. K., Wu, H., Tham, Y. C., Zhang, S., et al. (2025) · Communications Medicine · doi:10.1038/s43856-025-01137-6 · Cited by 5
“…ﬁ culty in identifying eligible patients, and variability in disease progression collectively contribute to low enrollment rates, prolonged study timelines, and compromised data integrity in rare disease trials, ultimately resulting in higher failure rates compared to non-rare disease trials 5,6 .”
Integrating Single‐Cell Transcriptome‐Wide Mendelian Randomization and Differentially Expressed Gene Analyses to Prioritize Dynamic Immune‐Related Drug Targets for Cancers
Zheng, J., Yang, Q., Liu, H., Zhao, H., Wang, S., Liu, Y., Wu, X., Ding, Y., Ying, H., Ye, Y., et al. (2025) · Advanced Science · doi:10.1002/advs.202507451 · Cited by 6
Molecular Motif Learning as a pretraining objective for molecular property prediction
Liu, Z., Wang, C., Zheng, S., Wu, C., Feng, H., Xu, L. M., Zheng, Y., Rong, L., & Li, P. (2025) · Nature Communications · doi:10.1038/s41467-025-66685-w · Cited by 10
“Traditional wet-lab experimental methods todeterminethesepropertiesaretime-consumingandcostly 19,20 .”
Advancing target discovery through disease-specific integration of multi-modal target identification models and comprehensive benchmarking system
Leung, H., Duan, C., Gou, W., Chen, J., Xin, Y., Zheng, Z., Naumov, V., Gennert, D. G., Zhang, M., Aliper, A., et al. (2026) · Scientific Reports · doi:10.1038/s41598-026-47765-3 · Cited by 5
CavitOmiX Drug Discovery: Engineering Antivirals with Enhanced Spectrum and Reduced Side Effects for Arboviral Diseases
Parigger, L., Krassnigg, A., Hetmann, M., Hofmann, A., Gruber, K. F., Steinkellner, G., & Gruber, C. C. (2024) · Viruses · doi:10.3390/v16081186 · Cited by 5
“Sun et al. states that 9 out of 10 clinical trials are not successful, 40–50% of which fail due to lack of efficiency and 30% fail due to toxicity or side effects [13,14].”
Background
3D cultivation of non-small-cell lung cancer cell lines using four different methods
Malmros, K., Kirova, N., Kotarsky, H., Carlsén, D., Mansour, M. S. I., Magnusson, M., Prabhala, P., & Brunnström, H. (2024) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-024-06003-x · Cited by 5
“Development of new anti-cancer drugs takes time, and many substances that show promising results in vitro do not result in approved drugs for clinical use, often due to limited effect in vivo (Harrison 2016; Dowden and Munro 2019).”
The missing enzymes: a call to update pharmacological profiling practices for better drug safety assessment
Maciag, M., & Karamyan, V. T. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c02228 · Cited by 5
Investigational Therapies and Patients’ Autonomy
Papakonstantinou, T., & Kolettis, T. M. (2020) · Canadian Journal of Bioethics · doi:10.7202/1073786ar · Cited by 5
“More importantly, only a small fraction of investigational treatments, qualifying for clinical testing, eventually become part of the therapeutic armamentarium (4).”
Background
Improving the predictive power of xenograft and syngeneic anti-tumour studies using mice humanised for pathways of drug metabolism
Henderson, C. J., McLaren, A. W., Kapelyukh, Y., & Wolf, C. R. (2022) · F1000Research · doi:10.12688/f1000research.122987.1 · Cited by 6
Predicting routes of phase I and II metabolism based on quantum mechanics and machine learning
Öeren, M., Hunt, P. A., Wharrick, C. E., Ghomi, H. T., & Segall, M. (2023) · Xenobiotica · doi:10.1080/00498254.2023.2284251 · Cited by 5
“Thus, the failure rate of drug discovery and development is higher than 90% (Takebe et al. 2018; Dowden and Munro 2019; Hinkson et al. 2020; Sun et al. 2022).”
Optimizing the doses of cancer drugs after usual dose finding
Strohbehn, G. W., Stadler, W. M., Boonstra, P. S., & Ratain, M. J. (2023) · Clinical Trials · doi:10.1177/17407745231213882 · Cited by 5
“Finally, because the probability that a single candidate drug will win approval is low, 9 drugmakers are loath for a factor under their control—dose being one—to contribute to failure.”
Background
A microphysiological system for parallelized morphological and electrophysiological read-out of 3D neuronal cell culture
Jones, P. D., Molina-Martínez, B., Niedworok, A., & Cesare, P. (2024) · Lab on a Chip · doi:10.1039/d3lc00963g · Cited by 5
Patient-Derived Xenograft Models for Translational Prostate Cancer Research and Drug Development
Philp, L. (2024) · Methods in molecular biology · doi:10.1007/978-1-0716-3858-3_12 · Cited by 5
Visual analysis of drug research and development based on artificial intelligence
Wei, W., Song, C., Qi, C., Zhang, X., Zhang, X., Pu, R., & Ao, Y. (2024) · Journal of Holistic Integrative Pharmacy · doi:10.1016/j.jhip.2024.12.002 · Cited by 5
State-of-the-art analytical methods of viral infections in human lung organoids
Baumgardt, M., Hülsemann, M., Löwa, A., Fatykhova, D., Hoffmann, K., Kessler, M., Mieth, M., Hellwig, K., Frey, D., Langenhagen, A. K., et al. (2022) · PLoS ONE · doi:10.1371/journal.pone.0276115 · Cited by 5
In silico repurposing of CNS drugs for multiple sclerosis
Sardari, E., Ebadi, A., & Razzaghi‐Asl, N. (2023) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2023.104622 · Cited by 5
An overview to drug repurposing
Khambhati, K., Alessa, A. H., & Singh, V. (2024) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2024.03.026 · Cited by 5
Artificial Intelligence for Drug Toxicity and Safety
Joshi-Barr, S., & Wampole, M. E. (2024) · Springer eBooks · doi:10.1007/978-3-031-35529-5_134 · Cited by 5
Identifying and Validating New Drug Targets for Stroke and Beyond
Plump, A. S., & Smith, G. D. (2019) · Circulation · doi:10.1161/circulationaha.119.042005 · Cited by 4
“Today, the convergence of an innovationfriendly environment, a greater focus on translational science, and the emergence of powerful new therapeutic modalities beyond synthetic small molecules has led to dramatic shifts in approach, a greater focus on transformative therapies, and a gradual, but meaningful, uptick in…”
Background
Validation of a functional human AD model with four AD therapeutics utilizing patterned ipsc-derived cortical neurons integrated with microelectrode arrays
Caneus, J., Autar, K., Akanda, N., Grillo, M., Long, C. J., Jackson, M., Lindquist, S., Guo, X., Morgan, D., & Hickman, J. J. (2024) · Scientific Reports · doi:10.1038/s41598-024-73869-9 · Cited by 6
Ex Vivo Intestinal Organoid Models: Current State-of-the-Art and Challenges in Disease Modelling and Therapeutic Testing for Colorectal Cancer
Randall‐Demllo, S., Al-Qadami, G. H., Raposo, A. E., Ma, C., Priebe, I. K., Hor, M., Singh, R., & Fung, K. Y. C. (2024) · Cancers · doi:10.3390/cancers16213664 · Cited by 5
“The study of the drug approval process suggests that even of those drugs reaching Phase 2 or 3 clinical trials, up to 79% fail to meet the necessary safety and efficacy profile for approval [14,15].”
Background
Machine Learning Pipeline for Molecular Property Prediction Using ChemXploreML
Marimuthu, A. N., & McGuire, B. A. (2025) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.5c00516 · Cited by 7
LLM-enhanced multi-level knowledge distillation for molecular property prediction
Zhuang, L., Sun, Y., Jun, Z., Lu, Y., & Wang, H. (2025) · Knowledge-Based Systems · doi:10.1016/j.knosys.2025.114195 · Cited by 4
Dogs as a Model for Cancer: An Update
Fenger, J. M., & London, C. A. (2026) · Annual Review of Animal Biosciences · doi:10.1146/annurev-animal-111523-101930 · Cited by 5
Need for NAMs: A systematic evidence synthesis revealing over half a century of drug development failure
Filipova, D., Boomgaarden, W., Fox, L., Knight, A., Lickiss, B., Maaß, C., Neumann, G., Watkins, J. C., Herrmann, K., Ewart, L., et al. (2026) · NAM journal. · doi:10.1016/j.namjnl.2026.100119 · Cited by 4
“At the other end of the timeline, the most recent data examines compounds developed by 30 pharmaceutical firms from early 2015 to the end of 2017, yielding a mean failure rate of 93% (Dowden and Munro, 2019).”
Improving Covalent and Noncovalent Molecule Generation via Reinforcement Learning with Functional Fragments
Wang, Y., Wang, Z., Li, Y., et al. (2025) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.5c00944 · Cited by 4
Artificial Intelligence for Bone: Theory, Methods, and Applications
Yuan, D., Zhang, H., Tong, L., & Chen, D. (2025) · Advanced Intelligent Discovery · doi:10.1002/aidi.202500070 · Cited by 8
Clinical trials reimagined
Kwo, P. Y., & Patel, T. C. (2023) · Hepatology · doi:10.1097/hep.0000000000000436 · Cited by 5
Revolutionizing Medicine: Unleashing the Power of Real-World Data and AI in Advancing Clinical Trials
Raju, K. V., Rehana, S., Seethamraju, S. M., & Nori, L. P. (2024) · Brazilian Journal of Pharmaceutical Sciences · doi:10.1590/s2175-97902024e23980 · Cited by 7
Synthesis and toxicity of monothiooxalamides against human red blood cells, brine shrimp (Artemia salina), and fruit fly (Drosophila melanogaster)
Romero-Chávez, M. M., Macías-Hernández, C. E., Ramos-Organillo, Á., Jiménez‐Ruíz, E. I., Robles-Machuca, M., Ocaño‐Higuera, V. M., & Sumaya-Martínez, M. T. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e36182 · Cited by 5
“Approximately 30 % of clinical failures in drug development have been attributed to unmanageable toxicity [1 – 3].”
Background
Public sector replacement of privately funded pharmaceutical R&D: cost and efficiency considerations
Proudman, D. G., Desai, U. S., Gomes, D. A., Khomenko, M., Martin, S., Nellesen, D., Neumann, U., & Grabowski, H. G. (2024) · Journal of Medical Economics · doi:10.1080/13696998.2024.2405407 · Cited by 4
“When a lower probability of 6.7% was applied from a 2010–2017 study using a 30 firm sample, the resulting cost estimates increased to $171.2 billion 50 .”
Influential
Evolution of toxicity testing platforms from 2D to advanced 3D bioprinting for safety assessment of drugs
Shyam, R., Singh, R., Bajpai, M., Palaniappan, A., & Parthasarathi, R. (2024) · Bioprinting · doi:10.1016/j.bprint.2024.e00363 · Cited by 4
A benchtop brain injury model using resected donor tissue from patients with Chiari malformation
Chari, D. M., Tickle, J. A., Sen, J., Adams, C. F., Furness, D. N., Price, R., Kandula, V., & Tzerakis, N. (2022) · Neural Regeneration Research · doi:10.4103/1673-5374.355761 · Cited by 4
“However, approximately 79% of phase II trials fail to progress due to safety/efficacy issues (Dowden and Munro, 2019), based on the inherent difficulties in extrapolating drug data from animal to human (Basketter et al., 2012).”
Chemical Property Relation Guided Few-Shot Molecular Property Prediction
Yao, S., Feng, Z., Song, J., Jia, L., Zhong, Z., & Song, M. (2022) · International Joint Conference on Neural Networks (IJCNN) · doi:10.1109/ijcnn55064.2022.9892419 · Cited by 6
“It is recorded that drug discovery is a cost and time-intensive process with a failure rate of over 90%, taking more than 2 billion US dollars and about 10-15 years on average for an innovative drug to be developed and ﬁnally put on the market [2].”
Background
Novel Phenylene Lipids That Are Positive Allosteric Modulators of Glycine Receptors and Inhibitors of Glycine Transporter 2
Gallagher, C. I., Frangos, Z. J., Sheipouri, D., Shimmon, S., Duman, M.-N., Jayakumar, S., Cioffi, C. L., Rawling, T., & Vandenberg, R. J. (2023) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.3c00167 · Cited by 4
Mutate and Conjugate: A Method to Enable Rapid In-Cell Target Validation
Thomas, A., Serafini, M. T., Grant, E. K., Coombs, E. A. J., Bluck, J. P., Schiedel, M., McDonough, M. A., Reynolds, J. K., Lee, B., Platt, M. A., et al. (2023) · ACS Chemical Biology · doi:10.1021/acschembio.3c00437 · Cited by 3
Identification of potential FAK inhibitors using mol2vec molecular descriptor-based QSAR, molecular docking, ADMET study, and molecular dynamics simulation
Hằng, N. T., My, T. T. K., Anh, L. T. V., Anh, P. T. V., Anh, T. D. H., & Phuong, N. V. (2024) · Molecular Diversity · doi:10.1007/s11030-024-10839-3 · Cited by 5
“According to Helen Dowden, et al. [35] and Richard K. Harrison [36], the failure rate of research and development of new drugs in phase I/II was as high as 90%, of which 40–45% of cases were related to problems of toxicity and drug-like properties.”
Use of SRS microscopy for imaging drugs
Steven, C. F., Chiarparin, E., Hulme, A. N., & Brunton, V. G. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-85158-9.00030-0 · Cited by 4
Editorial: Insights in drug metabolism and transport: 2021
Piñeiro-Llanes, J., Stec, D. E., & Cristofoletti, R. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1198598 · Cited by 4
Discovery of novel compounds and target mechanisms using a high throughput, multiparametric phenotypic screen in a human neuronal model of Tuberous SclerosisPreprint
Williams, L. A., Ryan, S. J., Joshi, V., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.02.22.581652 · Cited by 4
“Successful drug development for central nervous system (CNS) disorders remains a challenge, with clinical failures outpacing successes 1 .”
Background
Artificial intelligence in drug discovery: Current applications and future directions
Alanazi, A. A. A., Fahad, ‏. I. A. A., Almorshed, A. S. A., Alrbian, A. A. M., Alnughaymishi, A. A. S., Al-Mutairi, N. H. B., Alajmi, A. A., & Otaibi, S. G. A. (2022) · International Journal of Health Sciences · doi:10.53730/ijhs.v6ns10.15290 · Cited by 5
“Furthermore, the probability of progressing a drug from Phase I clinical trials to market is discouragingly low, with a success rate below 10% [2].”
Background
Recent advances and future perspectives of long-acting ophthalmic preparations (LAOPs) in clinical applications
Wang, B., Zhang, M., Chen, W., Yin, C., Zhao, H., Chen, G., & Cao, F. (2025) · Biomaterials Science · doi:10.1039/d5bm00453e · Cited by 3
Lost in translation: rethinking animal models of progressive MS (an industry perspective)
von Raison, F., Zaratin, P., Stangel, M., Shimshek, D. R., Nuesslein‐Hildesheim, B., Locatelli, G., Collin, L., Foo, L. C., Jafari, M., Peelen, E., et al. (2025) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2025.106644 · Cited by 4
Trends in nephrology: from ‘translational research’ in animals to research in humans
Podestà, M. A., & Steiger, S. (2025) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfaf157 · Cited by 3
Translating Structural Hierarchy and Mechanobiology of Bone in Microphysiological Systems
Dhandapani, R., Sathyanarayanan, K., & Pradhan, S. (2025) · Small · doi:10.1002/smll.202509536 · Cited by 3
A novel framework for assessing large language models in computational drug design: Targeting AXL receptor tyrosine kinase for cancer therapy
Shams, F., Khanehzar, E., Jafari, A., Poustforoosh, A., Abedi, M., & Jafarinia, S. (2026) · In Silico Research in Biomedicine · doi:10.1016/j.insi.2025.100171 · Cited by 3
Advances in the pathophysiological study of brain development: application of cerebral organoid combined with Spatial omics technology
Wang, J., Sun, Z., Zhou, Y., Wang, L., & Liu, J. (2026) · Stem Cell Research & Therapy · doi:10.1186/s13287-025-04885-3 · Cited by 3
“This has contributed to high failure rates in clinical trials, with only 6–7% of pre-clinical drugs successfully transitioning to approval due to issues of inefficacy and toxicity [143].”
Heterogeneity and optimal study design between cell lines in induced pluripotent stem cell-based cardiac disease modeling
Maas, R. G. C., Denning, C. N., & Sluijter, J. P. G. (2026) · Stem Cells Translational Medicine · doi:10.1093/stcltm/szag001 · Cited by 4
Eliminating Unnecessary Animal Testing
Høeg, T. B., Kozlowski, S., Saber, H., & Makary, M. A. (2026) · JAMA · doi:10.1001/jama.2026.7074 · Cited by 4
AI and machine learning for predicting in vitro/preclinical drug toxicities and adverse events in clinical patients
Jusko, N. M., Karekar, N., Cao, A., & Sun, D. (2026) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2026.05.028 · Cited by 5
Retrospective Analysis of the Impact of the “Escape from Flatland” Publication on the Merck & Co., Inc., Small Molecule Portfolio
Garry, O. L., Cheng, A. C., Northrup, A. B., Merchant, R. R., & Yeung, C. S. (2026) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6c01038 · Cited by 5
Meeting report: the ALPHA project: a stakeholder meeting on lupus clinical trial outcome measures and the patient perspective
Buie, J. N. J., Bloch, L., Morand, E. F., et al. (2023) · Lupus Science & Medicine · doi:10.1136/lupus-2023-000901 · Cited by 3
Cardiovascular Organoids/3D Models Review Series: an Introduction
Hilaire, C. S. (2023) · Circulation Research · doi:10.1161/circresaha.123.322561 · Cited by 3
Pharmacometabolomics: General Applications of Metabolomics in Drug Development and Personalized Medicine
Tran, D. T., & Dahlin, A. (2023) · Springer eBooks · doi:10.1007/978-3-031-39094-4_5 · Cited by 4
BABAÇU: EXPLORANDO SUAS CARACTERÍSTICAS E POTENCIALIDADES
Santos, S. S., de Carvalho, R. B. F., Silva, F. M. D. S. E., Lima, S. D. S., & Nunes, L. C. C. (2023) · doi:10.22533/at.ed.6652311126 · Cited by 3
MolBench: A Benchmark of AI Models for Molecular Property Prediction
Jiang, X., Tan, L., Cen, J., & Zou, Q. (2024) · Lecture notes in computer science · doi:10.1007/978-981-97-0316-6_4 · Cited by 3
Improving the predictive accuracy of efficacy evaluation using tumor orthotopic transplant and resection model
Li, X., Luo, L., & Qian, H. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1309876 · Cited by 3
“The development of anti-cancer drugs or therapies is a long, costly, and high-risk process and nine out of ten candidate drugs or therapies fail in clinical trials (Dowden and Munro, 2019).”
Background
BoostDILI: Extreme Gradient Boost-Powered Drug-Induced Liver Injury Prediction and Structural Alerts Generation
Chutia, H., Borah, G. S., Mahanta, H. J., & Nagamani, S. (2025) · Chemical Research in Toxicology · doi:10.1021/acs.chemrestox.4c00532 · Cited by 4
DESIGN AND COMPUTATIONAL ANALYSIS OF NEW ISATIN-IMINE HYBRIDS AS SELECTIVE HDAC6 INHIBITORS
AL-GBURI, K. M. H., Naser, N. H., & Jasamai, M. (2025) · International Journal of Applied Pharmaceutics · doi:10.22159/ijap.2025v17i3.53658 · Cited by 3
“Poor pharmacokinetic profile and toxicity are crucial aspects of drug development, and they are responsible for 40% and 35% of drug development failure, respectively [28, 29].”
Analyzing collaboration dynamics in new drug R&D: A case study of two lipid-lowering drugs
Zhang, N., Guo, H., Zhang, M., et al. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1516882 · Cited by 3
Characterization of human living myocardial slices culture-induced adaptations: a translational perspective
van der Geest, J. S. A., Benavente, E. D., van Ham, W. B., et al. (2025) · Journal of Molecular and Cellular Cardiology Plus · doi:10.1016/j.jmccpl.2025.100465 · Cited by 3
Comprehensive Analysis of Clinically Discontinued Compounds Using an In Vitro Secondary Pharmacology Panel to Predict Potential Safety Risks during Drug Development
Albert, V., Skinner, D., Karnwal, S., Guili, L. N., Vazquez, M., Ledezma, O., Shaffer, R., Celniker, A., Cruz, A. D. L., Caliendo, M., et al. (2025) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.5c00452 · Cited by 2
Scientific diligence for oncology drugs: a pharmacology, translational medicine and clinical perspective
Parasrampuria, D. A., Bandekar, R. R., & Puchalski, T. A. (2020) · Drug Discovery Today · doi:10.1016/j.drudis.2020.07.014 · Cited by 3
Highly Parallelized, Multicolor Optogenetic Recordings of Cellular Activity for Therapeutic Discovery Applications in Ion Channels and Disease-Associated Excitable Cells
Borja, G. B., Zhang, H., Harwood, B. N., Jacques, J., Grooms, J., Chantre, R., Zhang, D., Barnett, A., Werley, C. A., Yang, L., et al. (2022) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2022.896320 · Cited by 3
Anticancer activity, hTERT expression and telomere length analysis in SH-SY5Y neuroblastoma cell lines applied to docetaxel
İnandıklıoğlu, N., Taş, A., Ağbektas, T., Tunçbilek, Z., Raheem, K. Y., Cinar, G., & Siliğ, Y. (2022) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2022.134346 · Cited by 3
Academic drug discovery in an age of research abundance, and the curious case of chemical screens toward drug repositioning
Datti, A. (2023) · Drug Discovery Today · doi:10.1016/j.drudis.2023.103522 · Cited by 3

Authors: Dowden, H., & Munro, J.
Corresponding author: Munro, Jamie
Venue: Nature Reviews Drug Discovery
Publisher: Springer Science and Business Media LLC
Published: 2019-05-08
Volume: 18
Issue: 7
Pages: 495-496
ISSN: 1474-1776 (ISSN-L)
1474-1784
DOI: 10.1038/d41573-019-00074-z
OpenAlex: W2944466104
Cited by: 649
References: 0
Citations by year: 2026: 101 · 2025: 129 · 2024: 140 · 2023: 114 · 2022: 57 · 2021: 57 · 2020: 43 · 2019: 7
FWCI: 39.38
Type: journal article
Language: en
Open access: closed
Licence: www.springernature.com/gp/researchers/text-and-data-mining (tdm)
www.springernature.com/gp/researchers/text-and-data-mining (vor)
Locations: Nature Reviews Drug Discovery (publishedVersion)
PubMed (publishedVersion)
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Science, Research, and Medicine
Health Sciences › Medicine › Pharmacology (medical) › Historical Medical Research and Treatments
Health Sciences › Medicine › Internal Medicine › General Medicine and Therapeutics
Keywords: clinical success rate, therapeutic focus, drug development, clinical trial results, therapeutic areas

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Trends in clinical success rates and therapeutic focus

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cited by

Related

Metadata

Record

About these checks